| 2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.99.16 | 00 | Insecticides | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 64.5% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2935.00.29 | 00 | Anti-infective agents: | | | | |
| 2935.00.75 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 57.5% |
| 2936.25.00 | 00 | Vitamin B6 (Pyridoxine and related compounds with Vitamin B6 activity) and its derivatives | kg | Free | | 25% |
| 2936.26.00 | 00 | Vitamin B12 (Cyanocobalamin and related compounds with Vitamin B12 activity) and its derivatives | kg | Free | | 15.4￠/kg + 145.5% |
| 2936.28.00 | 00 | Vitamin E (Tocopherols and related compounds with Vitamin E activity) and its derivatives | kg | Free | | 15.4￠/kg + 63.5% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 46.5% |
| 3001 | | Glands and other organs for organotherapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included: | | | | |
| 3002 | | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: | | | | |
| 3002.10.01 | | Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes | | Free | | Free |
| 3003 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale: | | | | |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.90.91 | 65 | Preparations primarily affecting the electrolytic, caloric or water balance: | | | | |
| 3004.90.91 | 05 | Anti-infective medicaments: | | | | |
| 3004.90.91 | 22 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 50 | Medicaments primarily affecting the digestive system: | | | | |
| 3006.40.00 | 00 | Dental cements and other dental fillings; bone reconstruction cements | kg | Free | | 20% |
| 3204.11.35 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 63.5% |
| 3204.12.45 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A*,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P) 3% (SG) | 72% |
| 3204.13.60 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX,P) 3% (SG) | 71.7% |
| 3204.14.30 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX,P) 3% (SG) | 67.3% |
